Skip to main content

Table 2 Clinical characteristics after 6 weeks of dapagliflozin and placebo treatment, respectively

From: SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

  Placebo
Mean ± SD (change from baseline)
p-value vs. baseline Dapagliflozin
Mean ± SD (change from baseline)
p-value vs. baseline
BMI (kg/m2) 29.9 ± 4.2 (+ 0.1) 0.846 29.5 ± 4.1 (−0.3) < 0.001
HbA1c (%) 6.79 ± 0.8 (+ 0.12) 0.064 6.62 ± 0.7 (− 0.05) 0.224
Glucose
 Fasting (mg/dl) 135 ± 32 (+ 2.0) 0.325 114 ± 19 (−18) < 0.001
 Postprandial (mg/dl) 180 ± 67 (+ 1.0) 0.766 154 ± 46 (− 24) < 0.001
Office blood pressure
 Systolic (mmHg) 129 ± 13 (− 0.1) 0.340 126 ± 12 (− 4.0) 0.015
 Diastolic (mmHg) 79 ± 8.7 (− 1.0) 0.827 78 ± 8.8 (− 2.0) 0.058
 Heart rate (bpm) 67.8 ± 9.6 (− 1.3) 0.123 68.2 ± 10.6 (− 0.9) 0.332
24-h ambulatory blood pressure
 Systolic (mmHg) 129 ± 10.8 (− 0.5) 0.172 126 ± 10.8 (−3.0) 0.010
 Diastolic (mmHg) 77.1 ± 7.3 (0.0) 0.765 75.4 ± 7.7 (−2.0) 0.024
 Heart rate (bpm) 75.7 ± 9.5 (+ 1.4) 0.997 74.1 ± 7.6 (− 0.8) 0.849
 Haematocrit (%) 40.3 ± 3.1 (+ 0.2) 0.389 41.1 ± 2.9 (+ 1.0) < 0.001
 Serum sodium conc. (mmol/l) 138.1 ± 1.6 (− 0.5) 0.034 138.3 ± 1.6 (− 0.3) 0.308
 Urinary sodium excretion over 24 h (mmol/day) 222.5 ± 103.6 (− 6.0) 0.660 210.1 ± 71.2 (+ 6.5) 0.586
  1. N = 59. BMI body mass index, HbA1c glycated haemoglobin
  2. A standardised breakfast was given